225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer

C Kratochwil, F Bruchertseifer, FL Giesel… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer.
Recently, we started the first-in-human treatment with an α-radionuclide–labeled PSMA …

Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding

C Kratochwil, F Bruchertseifer, H Rathke… - Journal of Nuclear …, 2017 - Soc Nuclear Med
The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation
therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with …

PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617

C Kratochwil, FL Giesel, M Stefanova… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy
of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long …

Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy

M Sathekge, F Bruchertseifer, M Vorster… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA),
making this antigen a suitable target for radioligand therapy of the disease. Here we report …

Predictors and real-world use of prostate-specific radioligand therapy: PSMA and beyond

A Gafita, C Marcus, L Kostos, DM Schuster… - American Society of …, 2022 - ascopubs.org
PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer,
making it an excellent target for imaging and treating patients with prostate cancer. Several …

Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor …

C Kratochwil, F Bruchertseifer, H Rathke… - Journal of Nuclear …, 2018 - Soc Nuclear Med
The aim of this evaluation was to identify the first indicators of efficacy for 225Ac-labeled
prostate-specific membrane antigen (PSMA)–617 therapy in a retrospectively analyzed …

213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer

M Sathekge, O Knoesen, M Meckel… - European Journal of …, 2017 - Springer
Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) with 177Lu-PSMA
holds great promise as a safe treatment option in patients with metastasized castration …

Poor outcomes for patients with metastatic castration-resistant prostate cancer with low prostate-specific membrane antigen (PSMA) expression deemed ineligible for …

SP Thang, J Violet, S Sandhu, A Iravani… - European urology …, 2019 - Elsevier
Background Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic
castration-resistant prostate cancer (mCRPC) and represents a target for imaging and …

[HTML][HTML] Preclinical and clinical status of PSMA-targeted alpha therapy for metastatic castration-resistant prostate cancer

A Juzeniene, VY Stenberg, ØS Bruland, RH Larsen - Cancers, 2021 - mdpi.com
Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

[HTML][HTML] PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports

MJM Uijen, YHW Derks, RIJ Merkx… - European journal of …, 2021 - Springer
In the past decade, a growing body of literature has reported promising results for prostate-
specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate …